Raza Bokhari

Dr. Raza Bokhari is the Executive Chairman and CEO of Medicus Pharma (NASDAQ: MDCX), a clinical-stage pharmaceutical company. His career has been concentrated in the life sciences and healthcare sectors, with no demonstrated involvement in commodity markets, mining operations, or natural resource investing. For commodity and mining investors, his work falls outside the relevant domain.

Bokhari's current focus at Medicus Pharma centers on advancing two clinical programs through regulatory pathways. The first, SkinJect, is a drug-device product targeting dermatologic oncology, specifically Gorlin Syndrome and basal cell carcinoma. The second, Teverelix, is a GnRH antagonist (a drug class that suppresses certain hormones) being developed for prostate cancer, acute urinary retention, and endometriosis. Medicus recently received FDA clearance to proceed with a registrational study for SkinJect in Gorlin Syndrome patients and authorization from the UAE Department of Health for a genomics-guided Phase 2a trial of Teverelix in endometriosis.

His track record reflects experience navigating FDA regulatory processes, managing clinical-stage biotech pipelines, and engaging with lawmakers on healthcare policy. He has led Medicus through multiple IND submissions and clinical trial advancements across oncology, urology, and women's health indications.

There is no evidence in his public profile of commodity sector analysis, mining investment activity, or natural resource market commentary. Investors seeking mining and commodity expertise would not find relevant insights in Bokhari's public communications, which are focused on pharmaceutical development and healthcare regulation.